Pharmacovigilance in Italy: An overview

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Mazzitello, Carmela ^a   Esposito, Stefania ^a   De Francesco, Adele ^b   Capuano, Annalisa ^c   Russo, Emilio ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

ADRs; AIFA; Italian; legislation; monitoring

Indexed keywords

THALIDOMIDE;

ADVERSE DRUG REACTION; DRUG APPROVAL; DRUG DATABASE; DRUG INFORMATION; DRUG LEGISLATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; GOVERNMENT REGULATION; HUMAN; INFORMATION DISSEMINATION; INFORMATION RETRIEVAL; ITALY; MANDATORY REPORTING; MEDICATION ERROR; OFF LABEL DRUG USE; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; REVIEW; RISK MANAGEMENT;

EID: 84889583288     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120942     Document Type: Review

References (45)

1. World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: World Health Organization; 2002.
2. White T, Arakelian A, Rho JP. Counting the cost of drug-related adverse events. Pharmacoeconomics 1999;15:445-58.
3. Vallano A, Cereza G, Pedròs C, Agustí A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005;60:653-8.
4. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: The date. Br J Clin Pharmacol 1988;26:1-5.
5. Morgan K, Morgan SN. Quito Health Care State Rankings 1996. 4th ed. Lawrence, Kansas: Morgan Quitno Press; 1996.
6. Giofrè C, Scicchitano F, Palleria C, Mazzitello C, Ciriaco M, Gallelli L, et al. Pharmacovigilance and drug safety 2012 in Calabria (Italy): Adverse events analysis. J Pharmacol Pharmacother 2013 [In Press].
7. Baldinelli A, Ferrazin F, Pani L. Pharmacovigilance in the light of the new legislation: Implementation at national level. Italian Medicines Agency (AIFA). Rome: Office of Pharmacovigilance; 2010-2011.
8. Capuano A, Irpino A, Gallo M, Ferrante L, Illiano ML, Rinaldi B, et al. Regional surveillance of emergency-department visits for outpatient adverse drug events. Eur J Clin Pharmacol 2009;65:721-8.
9. Capuano A, Motola G, Russo F, Avolio A, Filippelli A, Rossi F, et al. Adverse drug events in two emergency departments in Naples, Italy: Anobservational study. Pharmacol Res 2004;50:631-6.
10. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2:1358.
11. Olsson S. The role of the WHO program on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998;19:1-10.
12. Available from: http://www.who-umc.org. [Last accessed on 2013 Jun 2].
13. Bégaud B, Chaslerie A, Haramburu F. Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique 1994;42:416-23.
14. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009;9:14.
15. Edwards IR. Who cares about pharmacovigilance? Eur J Clin Pharmacol 1997;53:83-8.
16. Available from: http://www.agenziafarmaco.gov.it. [Last accessed on 2013 Jun 2].
17. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009;32:99-110.
18. Carson JL, Strom BL, Maislin G. Screening for unknown effects of newly marketed drugs. In: Strom BL editor. Pharmacoepidemiology. 2nd ed. Chichester, West Sussex, England: John Wiley and Sons Ltd; 1994. p. 431-47.
19. Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Giaquinto C, Picelli G, et al. Idiopathic Acute Liver Injury in Paediatric Outpatients: Incidence and Signal Detection in Two European Countries. Drug Saf 2013 [In Press].
20. Esposito K, Capuano A, Sportiello L, Giustina A, Giugliano D. Should we abandon statins in the prevention of bone fractures? Endocrine 2013 [In Press].
21. Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol 1996;41:434-5.
22. Waller P. An introduction to pharmacovigilance. United States: A John Wiley & Sons, Ltd.; 2010.
23. Gallelli L, Palleria C, De Vuono A, Mumoli L, Vasapollo P, Piro B, et al. Safety and efficacy of generic drugs respect to brand formulation. Brief review and case series presentation. J Pharmacol Pharmacother 2013 [In Press].
24. Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, et al. Hypericum perforatum: Pharmacokinetic, mechanism of action, tolerability and clinical drug-drug interactions. Phytother Res 2013 [In Press].
25. Available from: http://eudravigilance.ema.europa.eu/human/index.asp [Last accessed on 2013 Jun 2].
26. http://www.ema.europa.eu/ema/[Last accessed on 2013 Jun 2].
27. Ministerial Decree Mar 20, 1980.
28. Ministerial Decree Jun 23, 1981.
29. Ministerial Decree Jul 28, 1984.
30. Art.9-DECREE 30 Oct 1987 (converted into Law 531/87).
31. D. Decree 18 Feb 1997, n. 44 (implementation of Dir 93/39/EEC).
32. D. Decree of 8 Apr 2003, n. 95.
33. D. M. Dec 12, 2003.
34. Leg. 219 24/04/2006-artt.129-134.
35. Legislative Decree no. 219 of 24/04/2006.
36. Available from: http://www.agenziafarmaco.gov.it/en/content/ postmarketing-surveillance. [Last accessed on 2013 Jun 2].
37. Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: A case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010;70:721-8.
38. Available from: http://www.who-umc.org/graphics/24965.pdf. [Last accessed on 2013 Jun 2].
39. Menniti M, Menniti A, Giofrè C, Russo E. Informaticsapplied to Pharmacovigilance. J Pharmacol Pharmacother 2013 [In Press].
40. Bertuola F, Morando C, Menniti-Ippolito F, Da Cas R, Capuano A, Perilongo G, et al. Association between drug and vaccine use and acute immunethrombocytopenia in childhood: A case-control study in Italy. Drug Saf 2010;33:65-72.
41. Bianciotto M, Chiappini E, Raffaldi I, Gabiano C, Tovo PA, Sollai S, et al. Drug use and upper gastrointestinal complications in children: A casecontrol study. Arch Dis Child 2013;98:218-21.
42. Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, et al. Safety of attention-deficit/hyper activity disorder medications in children: An intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol 2012;22:415-22.
43. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/ Other/2012/07/WC500129593.pdf [Last accessed on 2013 Jun 2].
44. Parretta E, Ianniello B, Ferrazin F, Rossi F, Capuano A. Italian post marketing surveillance for adverse event reports after MF59-adjuvanted H1N1 vaccination. Vaccine 2011;29:3708-13.
45. Scicchitano F, Giofrè C, Palleria C, Mazzitello C, Ciriaco M, Gallelli L, et al. Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci 2012;17:872-5.